Ferroptosis Inhibitors as Potential New Therapeutic Targets for Cardiovascular Disease / Zahra Shaghaghi, Shokouh Motieian, Maryam Alvandi, Amirhossein Yazdi, Bahareh Asadzadeh, Soghra Farzipour, Sahar Abbasi
Ferroptosis is a novel form of programmed cell death that occurs due to an increase in iron levels. Ferroptosis is implicated in a number of cardiovascular diseases, including myocardial infarction (MI), reperfusion damage, and heart failure (HF). As cardiomyocyte depletion is the leading cause of patient morbidity and mortality, it is critical to thoroughly comprehend the regulatory mechanisms of ferroptosis activation. In fact, inhibiting cardiac ferroptosis can be a useful therapeutic method for cardiovascular disorders. The iron, lipid, amino acid, and glutathione metabolisms strictly govern the beginning and execution of ferroptosis. Therefore, ferroptosis can be inhibited by iron chelators, free radical-trapping antioxidants, GPX4 (Glutathione Peroxidase 4) activators, and lipid peroxidation (LPO) inhibitors. However, the search for new molecular targets for ferroptosis is becoming increasingly important in cardiovascular disease research. In this review, we address the importance of ferroptosis in various cardiovascular illnesses, provide an update on current information regarding the molecular mechanisms that drive ferroptosis, and discuss the role of ferroptosis inhibitors in cardiovascular disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Mini-reviews in ... medicinal chemistry - 22(2022), 17, Seite 16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaghaghi, Zahra [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (16 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011180692 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011180692 | ||
| 003 | DE-627 | ||
| 005 | 20231128075921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011180692 | ||
| 035 | |a (KFL)prod_DARH_.365AAAB164B00A3A2EA5DAB835BD8702547FD806 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Shaghaghi, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ferroptosis Inhibitors as Potential New Therapeutic Targets for Cardiovascular Disease |c Zahra Shaghaghi, Shokouh Motieian, Maryam Alvandi, Amirhossein Yazdi, Bahareh Asadzadeh, Soghra Farzipour, Sahar Abbasi |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (16 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ferroptosis is a novel form of programmed cell death that occurs due to an increase in iron levels. Ferroptosis is implicated in a number of cardiovascular diseases, including myocardial infarction (MI), reperfusion damage, and heart failure (HF). As cardiomyocyte depletion is the leading cause of patient morbidity and mortality, it is critical to thoroughly comprehend the regulatory mechanisms of ferroptosis activation. In fact, inhibiting cardiac ferroptosis can be a useful therapeutic method for cardiovascular disorders. The iron, lipid, amino acid, and glutathione metabolisms strictly govern the beginning and execution of ferroptosis. Therefore, ferroptosis can be inhibited by iron chelators, free radical-trapping antioxidants, GPX4 (Glutathione Peroxidase 4) activators, and lipid peroxidation (LPO) inhibitors. However, the search for new molecular targets for ferroptosis is becoming increasingly important in cardiovascular disease research. In this review, we address the importance of ferroptosis in various cardiovascular illnesses, provide an update on current information regarding the molecular mechanisms that drive ferroptosis, and discuss the role of ferroptosis inhibitors in cardiovascular disease | ||
| 700 | 1 | |a Motieian, Shokouh |e verfasserin |4 aut | |
| 700 | 1 | |a Alvandi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdi, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Asadzadeh, Bahareh |e verfasserin |4 aut | |
| 700 | 1 | |a Farzipour, Soghra |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Sahar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini-reviews in ... medicinal chemistry |d Hilversum, the Netherlands [u.a.] : Bentham Science Publ., 2001 |g 22(2022), 17, Seite 16 |h Online-Ressource |w (DE-627)KFL000006394 |w (DE-600)2104083-7 |w (DE-576)273887203 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:17 |g pages:16 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=22&issue=17&spage=2271 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 17 |h 16 | ||